Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

New UK Guidance to be issued on Hepatitis C as 'silent epidemic'

Leading medical experts from throughout the UK will be gathering in Edinburgh today and tomorrow (21-22 April 2004) to arrive at a consensus on how best to treat and manage the 'silent epidemic' of hepatitis C - a virus which is estimated to be carried by over 400,000 people in the UK and which continues to spread globally, as the majority of carriers do not realise they have been infected.

21 Jun 2005

Scientists produce for the first time an infectious form of the hepatitis C virus in laboratory cultures of human cells

The finding, reported in the June 9 issue of Science Express, will allow scientists to study every stage of the HCV life cycle and develop drugs to treat this life-threatening disease that affects more than 170 million people around the world.

9 Jun 2005

Exposure to aflatoxins that contaminate crops in developing countries can be reduced by a simple, cost-effective intervention

Exposure to a cancer-causing toxin that contaminates crops in developing countries can be reduced by a simple, cost-effective intervention on post-harvest storage, concludes a study in this week’s issue of The Lancet.

3 Jun 2005

Global project to combat parasites that cause cancer and infection in millions

Many cancers are associated with infections (for example cervical cancer is linked to the human papilloma virus) but there is no stronger link between a human malignancy and a parasitic infection than that between cancer of the bile ducts and a liver fluke called Opisthorchis viverrini.

18 May 2005

Antiretroviral therapy may prevent excess risk of some cancers in people with HIV

In people infected with human immunodeficiency virus (HIV), highly active anti-retroviral therapy (HAART) may prevent most excess cases of Kaposi sarcoma and non-Hodgkin lymphoma, according to a new study in the March 16 issue of the Journal of the National Cancer Institute.

18 May 2005

Jefferson researcher’s results show promise for metastatic eye melanoma

But now, by simultaneously revving up the immune system and choking off the tumor’s oxygen supply, oncologists at Jefferson Medical College and the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia may have found a better way to battle this deadly cancer.

17 May 2005

Smoking may have a devastating effect on gastrointestinal health

Smoking may have a devastating effect on gastrointestinal health and increase a person's risk of developing pancreatic and liver cancer, according to new research presented today at Digestive Disease Week 2005 (DDW). Furthermore, data from the Nurses' Health Study shows that meat intake and smoking play a part in significantly increasing a woman's risk of colorectal cancer.

17 May 2005

More health benefits from green tea

Green tea appears to protect against cancer by affecting a "promiscuous" protein that pharmaceutical experts are already targeting in an effort to develop a new drug to stop the disease, scientists at the University of Rochester Medical Center have found.

16 May 2005

BMA calls for mass child vaccinations for hepatitis B virus (HBV)

The British Medical Association (BMA) has today called for all children in the UK to be immunised against a potentially fatal liver disease caused by the hepatitis B virus (HBV).

9 May 2005

Major Chinese breakthrough for pSivida - patent granted

This first patent grant in China is important as China has the highest incidence of primary liver cancer in the world with 345,844 cases in 2002 and is a logical target market for BrachySil. The potential lower cost of the Chinese registration pathway and the vast need of BrachySil like products make China an important commercial target.

9 May 2005

Small number of genes can predict response to chronic hepatitis C therapy

For the first time, physicians at University Health Network and University of Toronto have identified a small subset of genes that can predict whether a patient with chronic Hepatitis C will be able to respond to current treatments.

2 May 2005

Asians and Pacific Islanders have the highest levels of iron in their blood

UAB and international scientists studying iron-overload disorders have made the unexpected discovery that Asians and Pacific Islanders have the highest levels of iron in their blood of all racial/ethnic groups who were screened.

27 Apr 2005

High levels of immunosuppressant may lead to tumor recurrence

A new study on the incidence of liver cancer after transplant found that high levels of the immunosuppressant cyclosporine favored tumor recurrence and identified blood levels of the drug that should not be exceeded. Lower levels of cyclosporine levels did not affect rejection rates.

22 Apr 2005

pSivida moves to full development programme of pancreatic cancer product

pSivida Limited has announced that it has initiated a full development programme of its proprietary BrachySil product in a second key cancer indication. Development has commenced to evaluate the efficacy and safety of this novel brachytherapy product in pancreatic cancer, with the clinical programme scheduled to commence before the end of 2005.

7 Apr 2005

Chemoembolization, first-line treatment for liver cancer

New research by Jeff Geschwind, M.D., director of interventional radiology and associate professor at Johns Hopkins University School of Medicine, has shown that liver cancer patients, most of whom have inoperable tumours, could benefit from chemoembolization, a nonsurgical treatment option that delivers a high-dose of chemotherapy to the tumour while decreasing blood flow through the arteries feeding the tumour, known as embolization.

4 Apr 2005

Construction will enable pSivida to increase BrachySil production

Global nanotechnology company pSivida Limited has announced that it's UK manufacturing partner, Atomising Systems Ltd ("ASL"), has reached a key milestone in the manufacture of BrachySil, its lead product, by completing construction of a state of the art dedicated cleanroom facility to GMP specifications at its Sheffield plant in the United Kingdom. ASL is a world leader in high temperature atomising technology.

30 Mar 2005

New drug to treat chronic hepatitis B

The U.S. Food and Drug Administration (FDA) has given approval for a new drug to treat the potentially life-threatening disease Chronic hepatitis B.

30 Mar 2005

Hope of new treatments for liver damage

There is currently no cure for liver cirrhosis and a patient's only hope of survival is to receive a liver transplant.

28 Mar 2005

Strawberries destroy cancer cells

Researchers specializing in the health benefits of plant compounds have shown that quercetin, a phytonutrient found in abundance in strawberries and other fruits, can induce programmed self-destruction of human cancer cells.

23 Mar 2005

New study to evaluate Pegasys and Copegus to treat hepatitis C in liver transplant patients

Roche has initiated a new study to evaluate treatment strategies to reduce post-transplant recurrence of hepatitis C infection with the most prescribed hepatitis C treatment combination in the U.S., Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP).

21 Mar 2005